2035. Clinical and Economic Outcomes in Patients with Complicated Urinary Tract Infection (cUTI) and Complicated Intra-Abdominal Infection (cIAI) in Perú: Impact of Gram-Negative Organisms (GNO) Resistant to Antibiotics

Autor:	Homero Monsanto, Luis Hercilla, Lourdes Rodriguez, Gerson Galdos-Cardenas, Vanesa Moreno, Giancarlo Perez, Raul Gutierrez-Rodriguez, Juan C Orengo, Eresvita Ramirez, José M. Hidalgo, Ricardo Illescas
Rok vydání:	2019
Předmět:	medicine.medical_specialty Carbapenem medicine.drug_class business.industry Abdominal Infection Urinary system Antibiotics Cephalosporin Abstracts Patient room Infectious Diseases Oncology Internal medicine Poster Abstracts medicine In patient business Intra-Abdominal Infection medicine.drug
Zdroj:	Open Forum Infectious Diseases
ISSN:	2328-8957
DOI:	10.1093/ofid/ofz360.1715
Popis:	Background Delays in appropriate therapy of infections affect clinical outcomes. The aim of this study was to compare the clinical and economic outcomes of patients with cUTI and cIAI due to cephalosporin- and carbapenem-resistant GNOs to similar infections caused by nonresistant GNOs. Methods A retrospective cohort study of patients admitted to two tertiary care hospitals in Lima-Callao, Peru between January and December 2017. Patients with resistant strains were compared with those with nonresistant strains for the failure of initial antibiotic regimen (defined as worsened clinical status, change of initial antibiotic treatment, or in-hospital mortality), median length of stay (LOS), hospitalization ward cost and total hospitalization cost. Results A sample of 500 consecutive culture-positive patients were included: 429 (86%) with cUTI and 71 (14%) with cIAI (table). Conclusion cUTI caused by GNOs resistant to cephalosporins or carbapenems are associated with an incremental clinical and economic burden. The proportion of inappropriate therapy in patients with resistant infections is high. The cost of care for carbapenem-resistant cUTI was highest. The appropriate initial antibiotic choice may minimize the impact of GNO resistance on outcomes of patients with cIAI and cUTI. Disclosures All authors: No reported disclosures.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d730923eec4d5df6ad101d90da751027 https://doi.org/10.1093/ofid/ofz360.1715 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.